Investors

Press Releases

Date Title View
Toggle Summary Tetraphase to Present at Cowen and Company
Tetraphase to Present at Cowen and Company Watertown, MA – March 1, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including
View HTML
Toggle Summary BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic
BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic BARDA Awards Contract Worth up to $67 Million for the Development of a Novel Tetraphase Antibiotic Watertown, MA – February 16, 2012 – Tetraphase Pharmaceuticals, Inc., a clinical-stage
View HTML
Toggle Summary Tetraphase Appoints L. Patrick Gage, Ph.D., As Chariman of the Board
– Biopharmaceutical Industry Veteran to Help Advance Strategic Value of Tetraphase’s Promising Portfolio of Potent New Antibiotics –
View HTML
Toggle Summary Tetraphase to Present at Four Upcoming Conferences
Tetraphase to Present at Four Upcoming Conferences Watertown, MA – October 20, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria, including
View HTML
Toggle Summary NIAID Awards Contract Worth up to $36 Million for the Development of a Novel Tetraphase Antibiotic
NIAID Awards Contract Worth up to $36 Million for the Development of a Novel Tetraphase Antibiotic NIAID Awards Contract Worth up to $36 Million for the Development of a Novel Tetraphase Antibiotic Watertown, MA – October 19, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage
View HTML
Toggle Summary Tetraphase to Present at Two Upcoming Investor Conferences
Tetraphase to Present at Two Upcoming Investor Conferences Watertown, MA – September 15, 2011 – Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria,
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at ICAAC on Its Expanding Portfolio of Novel Broad Spectrum Antibiotics
– Seven Posters and a Presentation to Highlight Activity Against Multidrug-Resistant (MDR) Pathogens and Complicated Infections –
View HTML
Toggle Summary Tetraphase Pharmaceuticals President & CEO Guy Macdonald to Present at 2011 BIO International Convention
Tetraphase Pharmaceuticals President & CEO Guy Macdonald to Present at 2011 BIO International Convention Tetraphase Pharmaceuticals President & CEO Guy Macdonald to Present at 2011 BIO International Convention Watertown, MA – June 23, 2011 – Tetraphase Pharmaceuticals, Inc., a
View HTML
Toggle Summary Tetraphase Presents Data Demonstrating Robust Activity and Dosing Flexibility of Intravenous and Oral Next-Generation Antibiotic Candidates Targeting Complicated, Multidrug-Resistant Pathogens
– Presentations at the 21st ECCMID Highlight Activity of TP-434 in Both I.V. and Oral Step-Down Therapies and Potency and Oral Activity of TP-2758 Against Multidrug-Resistant Gram-Negative Pathogens –
View HTML
Toggle Summary Tetraphase to Present at Cambridge Health Institute's Antibacterial Drug Development Conference
– Company to Provide Insights on ‘Targeting Pathogens Resistant to Current Antibiotics’ Applauds WHO for Focus on Antimicrobial Resistance on World Health Day 2011 –
View HTML